| Title |
Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities
|
|---|---|
| Published in |
Drug Design, Development and Therapy, September 2016
|
| DOI | 10.2147/dddt.s111266 |
| Pubmed ID | |
| Authors |
Pinki Rawat, Saurabh Manaswita Verma |
| Abstract |
A series of chroman derivatives was designed, prepared, and examined for their anti-breast cancer and antiepileptic activities. All synthesized compounds yielded results that were in good agreement with spectral data. The bioassay showed that some of the resultant compounds exerted remarkable inhibitory effects on growth of human breast cancer cell line MCF-7. In particular, compound 6i (the concentration required for 50% inhibition of cell growth [GI50] =34.7 µM) exerted promising anticancer activity toward MCF-7 cell line. Additionally, compounds 6b, 6c, 6d, 6e, 6g, 6i, and 6l showed advanced antiepileptic activity than reference drugs. None of the compounds showed neurotoxicity, as determined by the rotarod test. The obtained results proved that these distinctive compounds could be relevant as models for future discovery and research, as well as for the production of more number of active derivatives. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 28% |
| Student > Ph. D. Student | 3 | 17% |
| Student > Master | 3 | 17% |
| Researcher | 1 | 6% |
| Unknown | 6 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 7 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 17% |
| Medicine and Dentistry | 2 | 11% |
| Agricultural and Biological Sciences | 1 | 6% |
| Unknown | 5 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2016.
All research outputs
#22,935,114
of 25,576,275 outputs
Outputs from Drug Design, Development and Therapy
#1,760
of 2,274 outputs
Outputs of similar age
#309,116
of 348,941 outputs
Outputs of similar age from Drug Design, Development and Therapy
#47
of 71 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,941 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.